Literature DB >> 26573286

Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.

Kanji Furuya1, Akiko Sasaki2, Yuko Tsunoda3, Mayumi Tsuji2, Yuko Udaka2, Hideto Oyamada2, Hiromichi Tsuchiya2, Katsuji Oguchi2.   

Abstract

Triple-negative breast cancer (TNBC), which does not show hormone sensitivity, is a poor prognosis disease without an established targeted treatment, so that establishing a therapeutic target for each subtype is desired. In addition, microRNA (miRNA), a non-cording RNA 19-25 nucleotide-longs in length, is known to be involved in regulating gene expression. We examined miRNA expression after exposure to eribulin, MDA-MB-231 cells, non-basal-like type of TNBC cell lines, and HCC1143 cells, basal-like type of TNBC cell lines. The activity of caspase-3 significantly increased compared to the control in MDA-MB-231, whereas no significant difference was observed in HCC1143. The expression level of 20-miRNAs significantly increased compared to the control in MDA-MB-231 after exposure to eribulin. The expression level of 6-miRNAs also significantly increased compared to the control in HCC1143. In these 2 cell types, miR-125b-1 and miR-195 were commonly expressed. While the expression level of miR-125b-1 decreased in both cells, the expression level of miR-195 increased in MDA-MB-231 and decreased in HCC1143. The expression level of miR-195 targeting Wnt3a significantly decreased compared to the control in MDA-MB-231, whereas it significantly increased in HCC1143. These results showed that exposure to eribulin highly increased the expression of miR-195 while it decreased the expression of Wnt3a in non-basal-like type of TNBC. Some miRNAs are known to regulate other signaling pathways involved in human pathogenesis by regulating the Wnt signaling pathway, and miRNA can act as a tumor-suppressing gene; therefore, miR-195 may serve as a therapeutic target in non-basal-like type of TNBC.

Entities:  

Keywords:  Breast cancer; Eribulin; MicroRNA; Triple negative; Wnt3a

Mesh:

Substances:

Year:  2015        PMID: 26573286     DOI: 10.1007/s13577-015-0126-2

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  32 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.

Authors:  Murray J Towle; Kathleen A Salvato; Bruce F Wels; Kimberley K Aalfs; Wanjun Zheng; Boris M Seletsky; Xiaojie Zhu; Bryan M Lewis; Yoshito Kishi; Melvin J Yu; Bruce A Littlefield
Journal:  Cancer Res       Date:  2010-12-02       Impact factor: 12.701

3.  Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.

Authors:  Fu-long Zhao; Yue-chao Dou; Xue-fei Wang; Da-cheng Han; Zhen-gang Lv; Shuang-lei Ge; Ya-kui Zhang
Journal:  Mol Biol Rep       Date:  2014-08-08       Impact factor: 2.316

4.  The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.

Authors:  Xiaohong Xie; Yuanyuan Hu; Leilai Xu; Yongqing Fu; Jue Tu; Hong Zhao; Shuo Zhang; Ri Hong; Xidong Gu
Journal:  Tumour Biol       Date:  2015-04-17

5.  The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Authors:  Elias Pean; Sigrid Klaar; Eva Gil Berglund; Tomas Salmonson; Jeanett Borregaard; Kenneth F Hofland; Jens Ersbøll; Eric Abadie; Rosa Giuliani; Francesco Pignatti
Journal:  Clin Cancer Res       Date:  2012-07-24       Impact factor: 12.531

6.  Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.

Authors:  Dariush Etemadmoghadam; George Au-Yeung; Meaghan Wall; Chris Mitchell; Maya Kansara; Elizabeth Loehrer; Crisoula Batzios; Joshy George; Sarah Ftouni; Barbara A Weir; Scott Carter; Irma Gresshoff; Linda Mileshkin; Danny Rischin; William C Hahn; Paul M Waring; Gad Getz; Carleen Cullinane; Lynda J Campbell; David D Bowtell
Journal:  Clin Cancer Res       Date:  2013-09-04       Impact factor: 12.531

Review 7.  Targeting basal-like breast cancers.

Authors:  Nandini Dey; Brian R Smith; B Leyland-Jones
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465

8.  Cables enhances cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers.

Authors:  C L Wu; S D Kirley; H Xiao; Y Chuang; D C Chung; L R Zukerberg
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

9.  CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells.

Authors:  Yuan Sun; Dianzhong Luo; D Joshua Liao
Journal:  J Carcinog       Date:  2012-08-30

10.  Wnt signaling in triple negative breast cancer is associated with metastasis.

Authors:  Nandini Dey; Benjamin G Barwick; Carlos S Moreno; Maja Ordanic-Kodani; Zhengjia Chen; Gabriella Oprea-Ilies; Weining Tang; Charles Catzavelos; Kimberly F Kerstann; George W Sledge; Mark Abramovitz; Mark Bouzyk; Pradip De; Brian R Leyland-Jones
Journal:  BMC Cancer       Date:  2013-11-10       Impact factor: 4.430

View more
  6 in total

1.  Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.

Authors:  Chun-Yao Li; Dan-Dan Xiong; Chun-Qin Huang; Rong-Quan He; Hai-Wei Liang; Deng-Hua Pan; Han-Lin Wang; Yi-Wen Wang; Hua-Wei Zhu; Gang Chen
Journal:  Med Sci Monit       Date:  2017-04-18

2.  Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer.

Authors:  Min Sun; Haibin Song; Shuyi Wang; Chunxiao Zhang; Liang Zheng; Fangfang Chen; Dongdong Shi; Yuanyuan Chen; Chaogang Yang; Zhenxian Xiang; Qing Liu; Chen Wei; Bin Xiong
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388

Review 3.  MicroRNA-195: a review of its role in cancers.

Authors:  Wanpeng Yu; Xiao Liang; Xiangdong Li; Yuan Zhang; Zhenqing Sun; Ying Liu; Jianxun Wang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

4.  miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization.

Authors:  Xiaobin Lin; Shuyi Wang; Min Sun; Chunxiao Zhang; Chen Wei; Chaogang Yang; Rongzhang Dou; Qing Liu; Bin Xiong
Journal:  J Hematol Oncol       Date:  2019-02-26       Impact factor: 17.388

Review 5.  Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer.

Authors:  Sara El-Sahli; Lisheng Wang
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

Review 6.  MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.

Authors:  Simona Ruxandra Volovat; Constantin Volovat; Irina Hordila; Dorin-Alexandru Hordila; Ciprian Camil Mirestean; Oana Tatiana Miron; Cristian Lungulescu; Dragos Viorel Scripcariu; Cati Raluca Stolniceanu; Assia Adrianova Konsoulova-Kirova; Cristina Grigorescu; Cipriana Stefanescu; Cristian Constantin Volovat; Iolanda Augustin
Journal:  Front Oncol       Date:  2020-11-20       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.